Clinical outcome for BRCA1 and BRCA2 mutation carriers after contralateral prophylactic mastectomy

被引：0
|
作者：
Schmidt, MK
van Sprundel, TC
Rookus, MA
Brohet, R
van Asperen, CJ
Rutgers, EJT
Tollenaar, RAEM
van't Veer, LJ
机构：
[1] Netherlands Canc Inst, Dept Pathol, NL-1066 CX Amsterdam, Netherlands
[2] Netherlands Canc Inst, Dept Epidemiol, Amsterdam, Netherlands
[3] Netherlands Canc Inst, Dept Surg, Amsterdam, Netherlands
[4] Leiden Univ, Med Ctr, Dept Surg, Leiden, Netherlands
[5] Leiden Univ, Med Ctr, Dept Clin Genet, Leiden, Netherlands
来源：
BREAST CANCER RESEARCH | 2005年 / 7卷 / Suppl 2期
关键词：
Breast Cancer; Contralateral Breast Cancer; BRCA2 Mutation Carrier; Mutation Testing; Contralateral Prophylactic Mastectomy;
D O I：
10.1186/bcr1096
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：S20 / S20
页数：1
相关论文
共 50 条
  • [21] Risks of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
    M Ahmed
    F Lalloo
    A Howell
    DG Evans
    Breast Cancer Research, 12
  • [22] Risks of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
    Ahmed, M.
    Lalloo, F.
    Howell, A.
    Evans, D. G.
    BREAST CANCER RESEARCH, 2010, 12 : S6 - S6
  • [23] Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
    Metcalfe, K.
    Gershman, S.
    Lynch, H. T.
    Ghadirian, P.
    Tung, N.
    Kim-Sing, C.
    Olopade, O. I.
    Domchek, S.
    McLennan, J.
    Eisen, A.
    Foulkes, W. D.
    Rosen, B.
    Sun, P.
    Narod, S. A.
    BRITISH JOURNAL OF CANCER, 2011, 104 (09) : 1384 - 1392
  • [24] Contralateral Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
    Graeser, Monika K.
    Engel, Christoph
    Rhiem, Kerstin
    Gadzicki, Dorothea
    Bick, Ulrich
    Kast, Karin
    Froster, Ursula G.
    Schlehe, Bettina
    Bechtold, Astrid
    Arnold, Norbert
    Preisler-Adams, Sabine
    Nestle-Kraemling, Carolin
    Zaino, Mohammad
    Loeffler, Markus
    Kiechle, Marion
    Meindl, Alfons
    Varga, Dominic
    Schmutzler, Rita K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) : 5887 - 5892
  • [25] Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation:: The hereditary breast cancer clinical study group
    Metcalfe, Kelly A.
    Lubinski, Jan
    Ghadirian, Parviz
    Lynch, Henry
    Kim-Sing, Charmaine
    Friedman, Eitan
    Foulkes, William D.
    Domchek, Susan
    Ainsworth, Peter
    Isaacs, Claudine
    Tung, Nadine
    Gronwald, Jacek
    Cummings, Shelly
    Wagner, Teresa
    Manoukian, Siranoush
    Moller, Pal
    Weitzel, Jeffrey
    Sun, Ping
    Narod, Steven A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (07) : 1093 - 1097
  • [26] Impact of Prophylactic Mastectomy in BRCA1/2 Mutation Carriers
    Rhiem, Kerstin
    Schmutzler, Rita
    BREAST CARE, 2014, 9 (06) : 385 - 389
  • [27] Prophylactic Mastectomy in BRCA1 and BRCA2 Mutation Carriers Very Low Risk for Subsequent Breast Cancer
    Kaas, Reinoutje
    Verhoef, Senno
    Wesseling, Jelle
    Rookus, Matti A.
    Oldenburg, Hester S. A.
    Peeters, Marie-Jeanne Vrancken
    Rutgers, Emiel J. T.
    ANNALS OF SURGERY, 2010, 251 (03) : 488 - 492
  • [28] Psychological follow up of BRCA1/BRCA2 mutation carriers opting for prophylactic mastectomy or surveillance and non-mutation carriers
    Lodder, LN
    Frets, PG
    Trijsburg, RW
    Meijers-Heijboer, EJ
    Klijn, JGM
    Seynaeve, C
    Tilanus, MMA
    Bartels, CCM
    Verhoog, LC
    Brekelmans, CTM
    Geel, AN
    Dukel, L
    Niermeijer, MF
    PSYCHO-ONCOLOGY, 2000, 9 (05) : 454 - 455
  • [29] Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up
    Olivier, RI
    van Beurden, M
    Lubsen, MAC
    Rookus, MA
    Mooij, TM
    van de Vijver, MJ
    van't Veer, LJ
    BRITISH JOURNAL OF CANCER, 2004, 90 (08) : 1492 - 1497
  • [30] Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up
    R I Olivier
    M van Beurden
    M A C Lubsen
    M A Rookus
    T M Mooij
    M J van de Vijver
    L J van't Veer
    British Journal of Cancer, 2004, 90 : 1492 - 1497
12345